AG
MRTX

Algert Global’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Algert Global’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,945
Closed -$1.05M – 1321
2023
Q4 		$1.05M Sell
17,945
-56,341
-76% -$3.17M 0.04% 605
2023
Q3 		$3.24M Buy
74,286
+770
+1% +$27.5K 0.15% 212
2023
Q2 		$2.66M Buy
73,516
+10,292
+16% +$424K 0.12% 289
2023
Q1 		$2.35M Buy
63,224
+34,079
+117% +$1.53M 0.11% 288
2022
Q4 		$1.32M Buy
29,145
+9,540
+49% +$617K 0.07% 455
2022
Q3 		$1.37M Buy
19,605
+7,805
+66% +$578K 0.08% 415
2022
Q2 		$792K Buy
11,800
+417
+4% +$26.5K 0.06% 576
2022
Q1 		$936K Buy
11,383
+8,728
+329% +$893K 0.06% 554
2021
Q4 		$389K Sell
2,655
-1,730
-39% -$269K 0.05% 636
2021
Q3 		$776K Buy
4,385
+1,641
+60% +$264K 0.1% 352
2021
Q2 		$443K Buy
2,744
+371
+16% +$59.6K 0.15% 199
2021
Q1 		$406K Buy
+2,373
New +$470K 0.13% 245
2020
Q2 		– Sell
-7,174
Closed -$551K – 519
2020
Q1 		$551K Buy
+7,174
New +$643K 0.23% 158

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Algert Global's MRTX Position: Q1 2024 in Review

Algert Global sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 17,945 shares — an estimated $1.05M sold.

Algert Global first reported a position in MRTX in Q1 2020 and held it in 13 quarters. The position peaked at $3.24M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Algert Global reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Algert Global sold 17,945 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.05M.
  • Algert Global first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 13 quarters.
  • Algert Global's Mirati Therapeutics, Inc. Common Stock position peaked at $3.24M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Algert Global's 13F filing for Q1 2024, filed 15 May 2024.